MCM
DGX icon

Moore Capital Management’s Quest Diagnostics DGX Stock Holding History

Moore Capital Management’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-79,118
Closed -$9.43M – 698
2020
Q4 		$9.43M Sell
79,118
-129,248
-62% -$15.8M 0.1% 150
2020
Q3 		$23.9M Buy
+208,366
New +$24.6M 0.46% 37
2014
Q3 		– Sell
-14,460
Closed -$848K – 421
2014
Q2 		$848K Buy
14,460
+6,660
+85% +$390K 0.02% 361
2014
Q1 		$452K Buy
+7,800
New +$418K 0.01% 365

Other funds holding DGX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FMI
Fiduciary Management Inc Milwaukee, Wisconsin $8.06B AUM 6.78% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DSA
Davis Selected Advisers Tucson, Arizona $21.8B AUM 23.45% 1-Year Est. Return
Nordea Investment Management
Nordea Investment Management Stockholm, Sweden $107B AUM 24.58% 1-Year Est. Return

Moore Capital Management's DGX Position: Q1 2021 in Review

Moore Capital Management sold out of Quest Diagnostics (DGX) in Q1 2021, closing a stake of 79,118 shares — an estimated $9.43M sold.

Moore Capital Management first reported a position in DGX in Q1 2014 and held it in 4 quarters. The position peaked at $23.9M in Q3 2020. 817 funds tracked by Wall St. Rank hold DGX as of Q1 2021.

  • Moore Capital Management reported no remaining Quest Diagnostics position as of Q1 2021 after selling out during the quarter.
  • Moore Capital Management sold 79,118 Quest Diagnostics shares in Q1 2021, an estimated $9.43M.
  • Moore Capital Management first reported a position in Quest Diagnostics in Q1 2014 and held it in 4 quarters.
  • Moore Capital Management's Quest Diagnostics position peaked at $23.9M in Q3 2020.
  • 817 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2021.

Based on Moore Capital Management's 13F filing for Q1 2021, filed 17 May 2021.